Ahmed Elkhanany

Ahmed Elkhanany
Assistant Professor

Associate Scientist (C), O'Neal Comprehensive Cancer Center , School of Medicine
Associate Scientist, Experimental Therapeutics , O'Neal Comprehensive Cancer Center
Associate Scientist (C), Center for Clinical and Translational Science (CCTS) , General Clinical Research Center
Assistant Professor (P), Medicine - Hematology & Oncology , Department of Medicine

Selected Publications

Academic Article

Year	Title	Altmetric
2021	Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T-Cell Exhaustion 2021
2021	Disparities in Breast Cancer Associated With African American Identity.. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 41:e29-e46. 2021
2021	Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021 2021
2020	Contribution of immune cells to glucocorticoid receptor expression in breast cancer. International Journal of Molecular Sciences. 21:1-17. 2020
2020	Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 1.2020 featured updates to the NCCN guidelines 2020
2019	Primary and secondary breast angiosarcoma: single center report and a meta-analysis. Breast Cancer Research and Treatment. 178:523-533. 2019
2018	Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Research and Treatment. 167:89-99. 2018
2015	Clinical correlates of common corneal neovascular diseases: A literature review. International Journal of Ophthalmology. 8:182-193. 2015
2015	Cocaine induced pleural and pericardial effusion syndrome. 2015
2014	GAIP interacting protein C-Terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways. PLoS ONE. 9. 2014
2013	Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. International Journal of Cancer. 132:1201-1212. 2013

Principal Investigator On

Private Grant awarded by NOVARTIS PHARMACEUTICALS CORPORATION

Private Grant awarded by TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM

Private Grant awarded by Pfizer Inc., U.S. Pharmaceuticals Group

Private Grant awarded by SERMONIX PHARMACEUTICALS INC

Private Grant awarded by F.Hoffmann-La Roche Ltd.

Private Grant awarded by TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM

TBCRC -AURORA US: A Prospective Biospecimen Repository in Metastic Breast Cancer awarded by Johns Hopkins University

XUAB 2023-IMMUNe mOdulation in Early Stage Estrogen Receptor Positive Breast Cancer Treated with NeoADjuvant Avelumab, Palbociclib, and Tamoxifen: The ImmunoADAPT Study awarded by Johns Hopkins University

XUAB2107-A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA) awarded by HOOSIER CANCER RESEARCH NETWORK

Investigator On

ECOG-ACRIN Purchase Service Agreement awarded by Eastern Cooperative Oncology Group

FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE R20-080 awarded by ECOG-ACRIN CANCER RESEARCH GROUP

Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect awarded by University of Wisconsin-Madison

Private Grant awarded by Pfizer Pharmaceuticals

Private Grant awarded by NOVARTIS PHARMACEUTICALS CORPORATION

Private Grant awarded by SEATTLE GENETICS, INC.

Private Grant awarded by DAIICHI SANKYO, INC.

Private Grant awarded by LILLY USA, LLC

UAB 1174: Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2 awarded by QUANTUM LEAP HEALTH CARE

UAB 1428 – A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer (HOG Trial) awarded by HOOSIER CANCER RESEARCH NETWORK

UAB 17127-A Phase 1b Trial of Fulvestrant, Palbociclib (CDK4/6 inhibitor) and Erdafitinib (JNJ-42756493, Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2–/FGFR-Amplified Metastatic Breast Cancer (MBC) awarded by VANDERBILT UNIVERSITY

[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Women with Newly Diagnosed Metastatic Breast Cancer (R20-146) awarded by ECOG-ACRIN CANCER RESEARCH GROUP

Education And Training

Doctor of Medicine, Alexandria University 2011

Full Name

Ahmed Elkhanany